Ademi LLP Investigates XOMA for Possible Violations
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1 hour ago
0mins
Should l Buy XOMA?
Source: PRnewswire
- Shareholder Rights Investigation: Ademi LLP is investigating XOMA for potential breaches of fiduciary duty in its transaction with Ligand, which has a total equity value of approximately $739 million, with shareholders set to receive $39 per share, potentially impacting long-term shareholder interests.
- Legal Risk Exposure: The transaction agreement imposes significant penalties for accepting competing bids, which may limit shareholder options and lead to potential losses, thereby affecting the company's governance structure and shareholder value.
- Internal Conflicts of Interest: XOMA insiders stand to gain substantial benefits from change of control arrangements, raising concerns about whether the board is fulfilling its fiduciary duties to all shareholders, which could impact the company's reputation and shareholder trust.
- Litigation Outlook: Ademi LLP specializes in shareholder litigation related to buyouts, mergers, and individual rights, and the investigation's findings could lead to legal actions against XOMA's board, potentially affecting the company's operations and shareholder protections.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy XOMA?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on XOMA
Wall Street analysts forecast XOMA stock price to rise
5 Analyst Rating
4 Buy
1 Hold
0 Sell
Strong Buy
Current: 37.900
Low
50.00
Averages
71.00
High
97.00
Current: 37.900
Low
50.00
Averages
71.00
High
97.00
About XOMA
XOMA Royalty Corporation is a biotechnology royalty aggregator. The Company’s royalty aggregator business is primarily focused on early to mid-stage clinical assets, primarily in Phase I and II, with significant commercial sales potential that are licensed to funded partners. The Company has a portfolio of economic rights and royalty payments associated with partnered commercial and pre-commercial therapeutic candidates. The Company's commercial assets include OJEMDA (tovorafenib), IXINITY, XACIATO, VABYSMO (faricimab svoa), DSUVIA (sufentanil sublingual tablet), and MIPLYFFA (arimoclomol). Its Phase III assets include Rilvegostomig (AZD2936), Ficlatuzumab (AV-299), Ovaprene, D-Fi (FCX-007), Seralutinib, Cetrelimab (JNJ-63723283), Ersodetug (RZ358), and Mezagitamab (TAK-079). Its Phase II assets include Acimtamig (AFM13), AFM24, Vosaroxin, Aldoxorubicin, G03-52-01, PBF-680, PBF-677, Vidutolimod (CMP-001), and RZ-402. Its others assets include COM902 and MT-0169.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Investor Rights Law Firm Investigates Multiple Companies
- Legal Investigation Launched: Halper Sadeh LLC is investigating Organon & Co. (NYSE:OGN) regarding its sale to Sun Pharmaceutical Industries Limited for $14.00 per share, which may involve breaches of fiduciary duties impacting shareholder confidence and company reputation.
- RE/MAX Transaction Scrutiny: The sale of RE/MAX Holdings, Inc. (NYSE:RMAX) to The Real Brokerage Inc. offers either 5.152 shares or $13.80 in cash per share, potentially limiting superior competing offers, prompting shareholders to consider their rights and options.
- XOMA Transaction Risks: XOMA Royalty Corporation (NASDAQ:XOMA) is involved in a sale to Ligand Pharmaceuticals Incorporated for $39.00 per share, with Halper Sadeh LLC possibly seeking increased compensation for shareholders, affecting the future shareholder structure of the company.
- Merger Impact Analysis: The merger between The Real Brokerage Inc. (NASDAQ:REAX) and RE/MAX will result in Real shareholders owning approximately 59% of the combined entity, potentially altering the competitive landscape and necessitating a reassessment of shareholder rights and risks post-merger.
See More
Investigation Alerts for Multiple Mergers
- XOMA Acquisition Deal: XOMA Royalty Corporation is set to be acquired by Ligand Pharmaceuticals for $39.00 per share, totaling approximately $739 million; however, this price is below its 52-week high of $42.38, raising concerns among shareholders about the fairness of the transaction.
- Organon Merger Case: Organon & Co. will be acquired by Sun Pharmaceutical for $14.00 per share in cash, with an enterprise valuation of $11.75 billion, and the investigation focuses on whether the Organon Board failed to treat shareholders fairly, potentially impacting shareholder rights.
- RE/MAX Acquisition Proposal: RE/MAX Holdings, Inc. will be acquired by The Real Brokerage, allowing shareholders to choose between 5.152 shares of the new company or $13.80 in cash per share, with investigations into whether the Board failed to handle the transaction fairly, affecting shareholder interests.
- Soleno Acquisition Investigation: Soleno Therapeutics, Inc. will be acquired by Neurocrine Biosciences for $53.00 per share, representing a total transaction value of approximately $2.9 billion, but this price is below its 52-week high of $90.32, raising questions about the Board's fairness in the deal.
See More
Monteverde Law Firm Investigates XOMA Sale to Ligand Pharmaceuticals
- Shareholder Protection: Monteverde & Associates is investigating the sale of XOMA Royalty Corporation to Ligand Pharmaceuticals, where shareholders will receive $39.00 per share in cash, aiming to ensure the fairness of the deal and protect shareholder interests.
- Law Firm Recognition: The firm is recognized as a Top 50 firm in the 2025 ISS Securities Class Action Services Report, showcasing its strong capabilities and successful track record in shareholder protection, thereby enhancing its reputation in the legal field.
- Risk-Free Consultation: Monteverde & Associates offers free consultations, allowing shareholders to obtain more information about the transaction without any cost or obligation, reflecting its commitment to client service and responsibility.
- Strategic Location: Headquartered in the Empire State Building in New York City, this national class action securities firm can leverage its geographical advantage to respond quickly to client needs and provide efficient legal services.
See More
Ademi LLP Investigates XOMA for Possible Violations
- Shareholder Rights Investigation: Ademi LLP is investigating XOMA for potential breaches of fiduciary duty in its transaction with Ligand, which has a total equity value of approximately $739 million, with shareholders set to receive $39 per share, potentially impacting long-term shareholder interests.
- Legal Risk Exposure: The transaction agreement imposes significant penalties for accepting competing bids, which may limit shareholder options and lead to potential losses, thereby affecting the company's governance structure and shareholder value.
- Internal Conflicts of Interest: XOMA insiders stand to gain substantial benefits from change of control arrangements, raising concerns about whether the board is fulfilling its fiduciary duties to all shareholders, which could impact the company's reputation and shareholder trust.
- Litigation Outlook: Ademi LLP specializes in shareholder litigation related to buyouts, mergers, and individual rights, and the investigation's findings could lead to legal actions against XOMA's board, potentially affecting the company's operations and shareholder protections.
See More
Ligand Pharmaceuticals to Acquire XOMA Royalty for $739 Million
- Acquisition Details: Ligand Pharmaceuticals has agreed to acquire XOMA Royalty for $39.00 per share in cash, totaling approximately $739 million, with unanimous board approval and expected closure in Q3 2026, indicating strong confidence in future growth.
- Financial Guidance Increase: The transaction is expected to be immediately accretive to Ligand's earnings per share, raising the 2026 revenue guidance to $270 million-$310 million and adjusted EPS guidance from $8.00-$9.00 to $8.50-$9.50, reflecting positive expectations from the acquisition.
- Portfolio Expansion: The acquisition will add over 120 commercial, clinical, and preclinical assets to Ligand's royalty portfolio, raising the royalty revenue outlook from $200 million-$225 million to $225 million-$250 million, further enhancing the company's competitive position in the market.
- Strategic Growth Opportunity: CEO Todd Davis stated that this acquisition will significantly strengthen and diversify the company's portfolio, adding seven marketed products and nearly doubling the Phase 2 and 3 assets, which is expected to create substantial value for shareholders.
See More
Ligand Pharmaceuticals to Acquire XOMA for $740M in Cash
- Acquisition Deal Size: Ligand Pharmaceuticals has reached a $740 million all-cash deal to acquire XOMA at $39 per share, with an announcement expected as soon as Monday, significantly enhancing Ligand's market position.
- Market Valuation Analysis: According to FactSet, XOMA had a market value of approximately $450 million as of last Friday, or nearly $700 million on a fully diluted basis, and this acquisition will enrich Ligand's portfolio with over 200 drugs and experimental treatments.
- Stock Price Reaction: Following the acquisition news, XOMA shares rose 2.9% in premarket trading to $39, indicating a positive market response and potentially reflecting investor confidence in Ligand's future growth prospects.
- Strategic Implications: This acquisition allows Ligand to not only expand its product line but also to further solidify its competitive advantage in the pharmaceutical industry, particularly in high-growth areas, which is expected to provide strong support for future revenue growth.
See More
Investor Rights Law Firm Investigates Multiple Companies
- Legal Investigation Launched: Halper Sadeh LLC is investigating Organon & Co. (NYSE:OGN) regarding its sale to Sun Pharmaceutical Industries Limited for $14.00 per share, which may involve breaches of fiduciary duties impacting shareholder confidence and company reputation.
- RE/MAX Transaction Scrutiny: The sale of RE/MAX Holdings, Inc. (NYSE:RMAX) to The Real Brokerage Inc. offers either 5.152 shares or $13.80 in cash per share, potentially limiting superior competing offers, prompting shareholders to consider their rights and options.
- XOMA Transaction Risks: XOMA Royalty Corporation (NASDAQ:XOMA) is involved in a sale to Ligand Pharmaceuticals Incorporated for $39.00 per share, with Halper Sadeh LLC possibly seeking increased compensation for shareholders, affecting the future shareholder structure of the company.
- Merger Impact Analysis: The merger between The Real Brokerage Inc. (NASDAQ:REAX) and RE/MAX will result in Real shareholders owning approximately 59% of the combined entity, potentially altering the competitive landscape and necessitating a reassessment of shareholder rights and risks post-merger.
See More
Investigation Alerts for Multiple Mergers
- XOMA Acquisition Deal: XOMA Royalty Corporation is set to be acquired by Ligand Pharmaceuticals for $39.00 per share, totaling approximately $739 million; however, this price is below its 52-week high of $42.38, raising concerns among shareholders about the fairness of the transaction.
- Organon Merger Case: Organon & Co. will be acquired by Sun Pharmaceutical for $14.00 per share in cash, with an enterprise valuation of $11.75 billion, and the investigation focuses on whether the Organon Board failed to treat shareholders fairly, potentially impacting shareholder rights.
- RE/MAX Acquisition Proposal: RE/MAX Holdings, Inc. will be acquired by The Real Brokerage, allowing shareholders to choose between 5.152 shares of the new company or $13.80 in cash per share, with investigations into whether the Board failed to handle the transaction fairly, affecting shareholder interests.
- Soleno Acquisition Investigation: Soleno Therapeutics, Inc. will be acquired by Neurocrine Biosciences for $53.00 per share, representing a total transaction value of approximately $2.9 billion, but this price is below its 52-week high of $90.32, raising questions about the Board's fairness in the deal.
See More
Monteverde Law Firm Investigates XOMA Sale to Ligand Pharmaceuticals
- Shareholder Protection: Monteverde & Associates is investigating the sale of XOMA Royalty Corporation to Ligand Pharmaceuticals, where shareholders will receive $39.00 per share in cash, aiming to ensure the fairness of the deal and protect shareholder interests.
- Law Firm Recognition: The firm is recognized as a Top 50 firm in the 2025 ISS Securities Class Action Services Report, showcasing its strong capabilities and successful track record in shareholder protection, thereby enhancing its reputation in the legal field.
- Risk-Free Consultation: Monteverde & Associates offers free consultations, allowing shareholders to obtain more information about the transaction without any cost or obligation, reflecting its commitment to client service and responsibility.
- Strategic Location: Headquartered in the Empire State Building in New York City, this national class action securities firm can leverage its geographical advantage to respond quickly to client needs and provide efficient legal services.
See More
Ademi LLP Investigates XOMA for Possible Violations
- Shareholder Rights Investigation: Ademi LLP is investigating XOMA for potential breaches of fiduciary duty in its transaction with Ligand, which has a total equity value of approximately $739 million, with shareholders set to receive $39 per share, potentially impacting long-term shareholder interests.
- Legal Risk Exposure: The transaction agreement imposes significant penalties for accepting competing bids, which may limit shareholder options and lead to potential losses, thereby affecting the company's governance structure and shareholder value.
- Internal Conflicts of Interest: XOMA insiders stand to gain substantial benefits from change of control arrangements, raising concerns about whether the board is fulfilling its fiduciary duties to all shareholders, which could impact the company's reputation and shareholder trust.
- Litigation Outlook: Ademi LLP specializes in shareholder litigation related to buyouts, mergers, and individual rights, and the investigation's findings could lead to legal actions against XOMA's board, potentially affecting the company's operations and shareholder protections.
See More
Ligand Pharmaceuticals to Acquire XOMA Royalty for $739 Million
- Acquisition Details: Ligand Pharmaceuticals has agreed to acquire XOMA Royalty for $39.00 per share in cash, totaling approximately $739 million, with unanimous board approval and expected closure in Q3 2026, indicating strong confidence in future growth.
- Financial Guidance Increase: The transaction is expected to be immediately accretive to Ligand's earnings per share, raising the 2026 revenue guidance to $270 million-$310 million and adjusted EPS guidance from $8.00-$9.00 to $8.50-$9.50, reflecting positive expectations from the acquisition.
- Portfolio Expansion: The acquisition will add over 120 commercial, clinical, and preclinical assets to Ligand's royalty portfolio, raising the royalty revenue outlook from $200 million-$225 million to $225 million-$250 million, further enhancing the company's competitive position in the market.
- Strategic Growth Opportunity: CEO Todd Davis stated that this acquisition will significantly strengthen and diversify the company's portfolio, adding seven marketed products and nearly doubling the Phase 2 and 3 assets, which is expected to create substantial value for shareholders.
See More
Ligand Pharmaceuticals to Acquire XOMA for $740M in Cash
- Acquisition Deal Size: Ligand Pharmaceuticals has reached a $740 million all-cash deal to acquire XOMA at $39 per share, with an announcement expected as soon as Monday, significantly enhancing Ligand's market position.
- Market Valuation Analysis: According to FactSet, XOMA had a market value of approximately $450 million as of last Friday, or nearly $700 million on a fully diluted basis, and this acquisition will enrich Ligand's portfolio with over 200 drugs and experimental treatments.
- Stock Price Reaction: Following the acquisition news, XOMA shares rose 2.9% in premarket trading to $39, indicating a positive market response and potentially reflecting investor confidence in Ligand's future growth prospects.
- Strategic Implications: This acquisition allows Ligand to not only expand its product line but also to further solidify its competitive advantage in the pharmaceutical industry, particularly in high-growth areas, which is expected to provide strong support for future revenue growth.
See More
